Business
Analysis of CTC-DNA and ctDNA using Illumina assay
Analysis of CTC-DNA and ctDNA using Illumina assay.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\n\n\n\n\nFor immediate release\n\n\n29 January 2025\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nNEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform \n \nFindings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single blood sample\n \nANGLE invited to present data at EACR-Illumina webinar on 6 February 2025\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce new, successful results for the Company's dual circulating tumour DNA (ctDNA) and CTC-DNA workflow using, for the first time, an end-to-end Illumina solution for analysis.\n \nOver the last six months, ANGLE has overcome technical issues to successfully use Illumina assays, coupled with their next generation sequencing (NGS) platform, to provide a complete solution for the dual analysis of CTCs and ctDNA. In the study, ctDNA was first isolated from the plasma and CTCs were isolated and harvested using the Parsortix® system from a single blood tube taken from 27 lung cancer patients. CTCs and ctDNA were then analysed using Illumina's customised 79 gene lung cancer panel with NGS completed on the Illumina NextSeq 2000 platform.\n \nIn the patients that had not received any treatment (n=8), 100% had cancer mutations identified that were identified only in the CTC-DNA and not in the ctDNA. In patients that had received treatment or were currently on treatment (n=19), 90% had cancer mutations identified only in the CTC-DNA and not in the ctDNA. There were also mutations identified in ctDNA alone that were not found in CTCs. This evidence confirms the importance of including CTC-DNA analysis alongside ctDNA so that clinically relevant cancer mutations are not missed. Analysing both analytes found twice as many mutations, which could be used as potential biomarkers to guide treatment.\n \nAs a result of these positive findings and their importance to both companies, Illumina has assigned their entire European Association for Cancer Research (EACR) webinar to ANGLE's findings. The webinar, entitled 'Complementary insights: Exploring the dual analysis of circulating t...